BioGenes is developing a point-of-care genetic testing kit that utilizes animal-free aptamers for the screening of major diseases. This technology enables rapid and accurate diagnostics, improving access to essential health information for patients and healthcare providers.
Funding
$7.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MTPEFounders
Product
Problem
Traditional disease screening methods often rely on animal-derived reagents, which can introduce ethical concerns, batch-to-batch variability, and potential contamination issues. Furthermore, centralized laboratory testing can lead to delays in obtaining results, hindering timely clinical decision-making.
Solution
BioGenes is developing a point-of-care diagnostic kit that utilizes animal-free aptamers for rapid screening of major diseases. By replacing antibodies with synthetic aptamers, the technology aims to provide a more consistent, ethical, and scalable diagnostic solution. The kit is designed to enable faster turnaround times and decentralized testing, potentially improving access to essential health information for both patients and healthcare providers. This approach seeks to streamline the diagnostic process and reduce reliance on traditional laboratory infrastructure.
Target Audience
The primary target audience includes healthcare providers, diagnostic laboratories, and point-of-care testing facilities seeking rapid, reliable, and animal-free diagnostic solutions.
Features
- Animal-free aptamer technology for disease screening
- Point-of-care testing capabilities for rapid results
- Simplified workflow for ease of use
- Potential for decentralized testing and improved access